Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK

J Med Econ. 2023 Jan-Dec;26(1):826-834. doi: 10.1080/13696998.2023.2225354.

Abstract

Aim: In a randomized control trial mid-regional proadrenomedullin (MR-proADM)-guided decision-making has been proven to safely reduce hospital admissions based on an accurate assessment of disease severity in the Emergency Department (ED). This study aimed to assess the impact of a MR-proADM-Guided Triage (MR-GT) versus standard Hospital Triage (HT) on clinical and economic outcomes in ED patients with suspected infection in Spain, Italy, Germany, and the UK, using Patient-Level Data (PLD) from two observational studies.

Methods: PLD was collected from patients enrolled at a Spanish hospital during two observational studies. Logistic regression was used to identify predictors of hospitalization. A patient-level simulation model was subsequently developed to evaluate the clinical and economic impact of MR-GT versus HT using results from the statistical analysis and country-specific cost data from the published literature. Probabilistic and deterministic sensitivity analyses were carried out.

Results: Four hundred seventy-three patients were enrolled in this study. MR-proADM had the strongest association with hospital admission, followed by age and National Early Warning Score (NEWS). In the simulation model, MR-GT was associated with an overall reduction in hospitalization relative to HT, equal to 22.6 percentage points (40.9 vs. 63.5%). In addition, the use of MR-GT would reduce the total hospital cost per patient presenting to the ED with suspected infection by roughly 30%, with a mean cost saving per patient of €626, €1,484, €1,154, and £1,113 in Spain, Italy, Germany, and the UK, respectively. The robustness of these findings was confirmed by sensitivity analyses.

Limitations: The statistical analyses were not performed on the same population simulated in the model. Clinical input parameters were assumed to be the same for all countries.

Conclusions: MR-proADM showed to be the main predictor of hospitalization. An MR-proADM decision algorithm provides cost savings in Spain, Italy, Germany, and the UK.

Keywords: D; D6; D60; I; I1; I10; MR-proADM; cost-effectiveness; emergency department; hospitalization; infection; patient-level simulation model.

Publication types

  • Randomized Controlled Trial
  • Observational Study

MeSH terms

  • Biomarkers
  • Cost-Benefit Analysis
  • Emergency Service, Hospital*
  • Humans
  • Prognosis
  • Spain
  • United Kingdom

Substances

  • Biomarkers